• Loading metrics

Altered mRNA Splicing, Chondrocyte Gene Expression and Abnormal Skeletal Development due to SF3B4 Mutations in Rodriguez Acrofacial Dysostosis

  • Felipe Marques ,

    Contributed equally to this work with: Felipe Marques, Jessica Tenney

    Affiliations Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, Brazil, Laboratório de Biotecnologia, Universidade CEUMA, Campus Renascença, São Luís-MA, Brazil

  • Jessica Tenney ,

    Contributed equally to this work with: Felipe Marques, Jessica Tenney

    Affiliations Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, Department of Pediatrics, Division of Genetics, University of California Los Angeles, Los Angeles, California, United States of America

  • Ivan Duran,

    Affiliation Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, California, United States of America


  • Jorge Martin,

    Affiliation Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, California, United States of America


  • Lisette Nevarez,

    Affiliation Department of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, California, United States of America

  • Robert Pogue,

    Affiliation Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, Brazil

  • Deborah Krakow , (DK); (DHC)

    Affiliations Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, California, United States of America, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, United States of America, Department of Human Genetics, University of California Los Angeles, Los Angeles, California, United States of America

  • Daniel H. Cohn , (DK); (DHC)

    Affiliations Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, California, United States of America, Department of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, California, United States of America

  • Bing Li

    Affiliation Department of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, California, United States of America


Altered mRNA Splicing, Chondrocyte Gene Expression and Abnormal Skeletal Development due to SF3B4 Mutations in Rodriguez Acrofacial Dysostosis

  • Felipe Marques, 
  • Jessica Tenney, 
  • Ivan Duran, 
  • Jorge Martin, 
  • Lisette Nevarez, 
  • Robert Pogue, 
  • Deborah Krakow, 
  • Daniel H. Cohn, 
  • Bing Li


9 Dec 2016: Marques F, Tenney J, Duran I, Martin J, Nevarez L, et al. (2016) Correction: Altered mRNA Splicing, Chondrocyte Gene Expression and Abnormal Skeletal Development due to SF3B4 Mutations in Rodriguez Acrofacial Dysostosis. PLOS Genetics 12(12): e1006502. View correction


The acrofacial dysostoses (AFD) are a genetically heterogeneous group of inherited disorders with craniofacial and limb abnormalities. Rodriguez syndrome is a severe, usually perinatal lethal AFD, characterized by severe retrognathia, oligodactyly and lower limb abnormalities. Rodriguez syndrome has been proposed to be a severe form of Nager syndrome, a non-lethal AFD that results from mutations in SF3B4, a component of the U2 small nuclear ribonucleoprotein particle (U2 snRNP). Furthermore, a case with a phenotype intermediate between Rodriguez and Nager syndromes has been shown to have an SF3B4 mutation. We identified heterozygosity for SF3B4 mutations in Rodriguez syndrome, confirming that the phenotype is a dominant disorder that is allelic with Nager syndrome. The mutations led to reduced SF3B4 synthesis and defects in mRNA splicing, primarily exon skipping. The mutations also led to reduced expression in growth plate chondrocytes of target genes, including the DLX5, DLX6, SOX9, and SOX6 transcription factor genes, which are known to be important for skeletal development. These data provide mechanistic insight toward understanding how SF3B4 mutations lead to the skeletal abnormalities observed in the acrofacial dysostoses.

Author Summary

The acrofacial dysostoses (AFD) are inherited disorders with abnormalities of the facial and limb bones. Rodriguez syndrome is a severe type of AFD that is usually lethal in the immediate perinatal period. Rodriguez syndrome has been proposed to be a severe form of Nager syndrome, a non-lethal AFD that results from mutations in SF3B4, a component of mRNA splicing machinery needed for proper maturation of primary transcripts. Furthermore, a case with a phenotype intermediate between Rodriguez and Nager syndromes has been shown to have an SF3B4 mutation. We found that mutations in SF3B4 produce Rodriguez syndrome, further demonstrating that it is allelic with Nager syndrome. The consequences of the mutations include abnormal splicing and reduced expression in growth plate chondrocytes of genes that are important for proper development of the skeleton, providing mechanistic insight toward understanding how SF3B4 mutations lead to the skeletal abnormalities observed in the acrofacial dysostoses.


The acrofacial dysostoses (AFD) are a genetically heterogeneous group of inherited disorders unified by craniofacial and limb abnormalities. At least 18 types of AFD have been characterized and, depending on the specific patterns of limb abnormalities, they have been further classified into those with preaxial limb abnormalities, those with postaxial defects and those which cannot be classified into the first two groups [1]. Miller syndrome (OMIM 263750) is a recessively inherited AFD, which results from pyrimidine biosynthesis defects due to mutations in DHODH [2]. Weyers AFD (OMIM 193530) is dominantly inherited phenotype caused by mutations in either EVC1 or EVC2, leading to defective cilia-mediated hedgehog signaling [3,4]. Dominant mutations affecting the RNA polymerase subunit POLR1A and ribosomal biogenesis have been found in AFD, Cincinnati type (OMIM 616462) [5]. Related mandibulofacial dysostosis phenotypes, including Treacher-Collins syndrome, can also result from defects in ribosomal biogenesis [6]. EFTUD2 encodes a GTPase which is a component of the U5 snRNP. Identification of EFTUD2 mutations in mandibulofacial dysostosis of the Guion-Almeida type (OMIM 610536) demonstrated that pre-mRNA splicing abnormalities could produce an AFD [7]. Also demonstrating a link with pre-mRNA splicing, mutations in EIF4A3 which affect the activity of the exon junction complex have been characterized in Richieri-Costa-Pereira syndrome (OMIM 268305) [8]. Similarly, mutations in the gene encoding the SF3B4 protein (also known as SAP49), a component of the U2 snRNP, have been found to produce Nager syndrome (OMIM 154400) [912]. While the genes involved in the characterized AFDs demonstrate that defects in a variety of basic biochemical processes can lead to these phenotypes, the underlying reasons for the distinct distribution of abnormalities in the craniofacies and distal limbs are not well understood.

Rodriguez syndrome (OMIM 201170) is a severe, usually perinatal lethal AFD characterized by severe retrognathia, hypertelorism with deep set eyes and deficient supra-orbital ridges, low set and posteriorly rotated ears, and oligodactyly with additional preaxial or postaxial abnormalities. Lower limb abnormalities, including fibular hypoplasia and equinovarus, are common and the spine, ribs and pelvis can also be involved. The initial description of the phenotype was a sibship of three affected offspring, suggesting recessive inheritance, but the seven cases reported subsequently were all sporadic in their families and did not recur, a pattern more consistent with de novo dominant mutations [1319].

Recently, McPherson et al. described a case of a surviving child with a phenotype intermediate between Rodriguez syndrome and the non-lethal Nager syndrome form of AFD [14]. The child was heterozygous for a mutation in SF3B4, supporting dominant mutations as underlying the phenotype and raising the possibility that these two AFDs are allelic. To test this hypothesis, we determined the sequence of SF3B4 in one case of classic Rodriguez syndrome and in a set of monozygotic twins with an intermediate phenotype, identifying heterozygosity for SF3B4 mutations in both families. At the biochemical level, the mutations led to reduced SF3B4 synthesis. Cartilage RNA-seq analysis identified reduced expression and/or altered splicing of target genes, including transcription factors known to be important in skeletal development, consistent with differential effects on pre-mRNA splicing and gene expression as underlying mechanisms of disease.


Clinical findings

Family R14-123.

The proband, International Skeletal Dysplasia Registry (ISDR) reference number R14-123A, was born to an unaffected 26-year-old G1P0 mother and 32-year-old unaffected father. Prenatal ultrasound at 29 weeks gestation indicated that the fetus was small for gestational age and had microcephaly, severe retrognathia, severely shortened and malformed appendicular bones, oligodactyly with prexial polydactyly, coarctation of the aorta and polyhydramnios (S1 Fig and Table 1), consistent with Rodriguez syndrome, a severe acrofacial dysostosis. Preterm labor and delivery ensued at 30 weeks gestation and the newborn survived for one hour. Postnatal findings showed multiple craniofacial and distal limb abnormalities including hypertelorism, bilateral microtia, severe micrognathia, severe rhizomelia, mesomelia and oligodactyly with duplication of the thumb. Radiographs demonstrated handlebar clavicles, small scapulae, hypoplastic humeri, humeroradial synostosis, absent pubis bone, malformed radii, absent ulnae, absent fibulae and oligodactyly with preaxial polydactyly on one hand, and oligodactyly on the other hand (Fig 1 and Table 1). The clinical findings are summarized in Table 1, and, along with the perinatal lethality, supported a diagnosis of Rodriguez syndrome.

Fig 1. Radiographic phenotypes of cases R14-123A and R08-269A & B.

(A) A/P radiograph of the chest of R14-123a showing small scapulae, 11 ribs, and abnormally formed hypoplastic humeri with radioulnar synostosis. (B) Hand radiograph showing oligodactyly, hypoplastic carpal bones and preaxial polydactyly. (C) Bilateral lower extremities showing hypoplastic or absent fibulae with small stippled calcanei. (D) A/P radiograph of R08-269A showing hypoplastic radii, oligodactyly, absent thumbs, thin fibulae, and club foot. (E) A/P radiograph of R08-269B showing 11 ribs, absent radii and ulnae.

Table 1. Summary of the ultrasound, clinical and radiographic findings.

Family R08-269.

The twin probands (ISDR cases R08-269A and B) were the offspring of a 33-year-old unaffected mother and an unaffected father. A prenatal ultrasound at 21 weeks gestation showed a monochorionic, diamniotic pregnancy, with both twins demonstrating limb abnormalities. There was significant size discordance between the twins, but both exhibited microcephaly, micrognathia and significant shortening of the appendicular bones, consistent with a form of acrofacial dysostosis. The pregnancy was interrupted at 22 weeks gestation. Postmortem findings confirmed the size discordance, facial dysmorphisms (Fig 1), bilateral microtia, severe micrognathia, left equinovarus in twin A, and right equinvarus in twin B (Table 1) also observed on ultrasound. Radiographic abnormalities included small scapulae, hypoplasia of the radii and thumbs in both twins, oligodacytly in twin A, and cervical vertebral and rib anomalies in twin B (Fig 1 and Table 1). The clinical findings were overall less severe than classic Rodriguez syndrome, including case R14-123, but more severe than would be expected for Nager syndrome, leading to a diagnosis intermediate between Nager and Rodriguez syndromes.

SF3B4 mutations cause Rodriguez syndrome

As SF3B4 is frequently mutated in patients with Nager syndrome and it had been suggested that Rodriguez syndrome might be an allelic disorder [912,14,20], we determined the sequences of SF3B4 in the two cases. Case R14-123A, with Rodriguez syndrome, was heterozygous for a de novo single base insertion (c.614_615insG; p.Asp205Glufs*281) in exon 3 (Fig 2A). Case R08-269B, with the intermediate phenotype, was heterozygous for a single base insertion (c.1060dupC; p.Arg354Profs*132) in exon 5 (Fig 2B). The latter mutation was previously found in two cases of Nager syndrome [9,12]. Both mutations led to frameshifts which started at different positions within the coding region but resulted in stop codons that terminated at the same position, which was beyond the normal stop codon (Fig 2D). Such mutations are referred to as a type of nonstop mutation and can lead to nonsense mediated decay of the transcripts [21,22]. Sequence analysis of amplified cDNA from R14-123A fibroblasts showed presence of some transcript derived from the mutant allele but always at a reduced level relative to the normal allele sequence (Fig 2C), consistent with instability of the mutant transcript. Based on these findings, we concluded that SF3B4 mutations cause Rodriguez syndrome.

Fig 2. Mutations in SF3B4.

(A,B) Electropherogram representation of genomic DNA fragments from controls (top), (A) case R14-123A (bottom), (B) case R08-269B (bottom). (C) The insertion in the SF3B4 cDNA of R14-123A (bottom) as compared with control (top). The positions of the insertion mutations are indicated by arrows. (D) Schematic diagram of predicted protein alterations caused by SF3B4 frameshift mutations. The blue bars correspond to the reference amino acid sequence and the red bars indicate altered amino acid sequences that begin at the mutation site. RNA recognition motifs (RRM) are shown as purple ovals.

Decreased expression of SF3B4 transcript and protein in Rodriguez syndrome

To characterize the effect of the mutations on overall SF3B4 expression, qRT-PCR was used to measure SF3B4 mRNA levels in cultured fibroblasts from case R14-123A and in chondrocytes from case R08-269A. There was about a 30% reduction in SF3B4 transcripts in both cases compared with controls (Fig 3A and 3B). As shown in Fig 3C, for R14-123A there was a corresponding decrease in SF3B4 protein relative to the control. Because there was a low level of the mutant transcript, which is predicted to encode a protein with an altered carboxyl-terminus that extends the length of the protein by 60 amino acids, we attempted to detect the mutant protein. The predicted molecular weight of the elongated protein is 52.8 kDa, which is 8.4 kDa larger than wild-type (WT) SF3B4. Western blotting was performed using an antibody to the amino-terminal end of the protein, which should be unaltered in both normal and mutant SF3B4, and with an antibody directed against the carboxyl-terminal end, which should only recognize WT SF3B4. As shown in Fig 3D, with a long exposure, the antibody against the amino-terminal end of the protein detected a faint protein migrating just above the SF3B4 WT protein, in a position corresponding to the predicted molecular weight of the mutant protein. This protein was not detected by the carboxyl-terminal antibody, as would be expected based on the mutation. The data were thus consistent with synthesis of a small amount of the mutant protein by the low level of mutant transcript present in the cultured cells (Fig 2C). Whether the abnormal protein is functional and contributes to the U2 snRNP and the Rodriguez syndrome phenotype is unknown. Immunofluorescence staining of cultured fibroblasts revealed nuclear localization of SF3B4, in agreement with its spliceosomal function in nucleus, with the fluorescence intensity appropriately reduced in cultured cells from the affected individual (Fig 3E).

Fig 3. Decreased expression of SF3B4 in Rodriguez syndrome.

(A,B) Detection of SF3B4 mRNA by quantitative RT-PCR in (A) R14-123A fibroblasts and (B) R08-269A chondrocytes. (C) Western blots (left panel) and signal quantification (right panel) of SF3B4 in R14-123A fibroblasts. Data in the bar graphs were collected from at least three replicates and were represented as mean ± standard deviation. *p<0.05; **p<0.01. (D) Detection of SF3B4 protein in R14-123A fibroblasts by Western blotting with the antibodies against the N- and C-termini of the SF3B4 protein, respectively. The asterisk identifies the elongated form of SF3B4 that was presumed to be derived from the mutant allele. SF3B1 protein was used as a loading control. (E) Immunostaining of human fibroblasts with anti-SF3B4 (green). Cell nuclei were stained with DAPI (blue).

Disruption of growth plate architecture due to SF3B4 mutation

The affected individuals exhibited shortening or absence of humeri, radii and ulnae, brachydactyly, and delayed ossification of the talus (Fig 1 and Table 1), which all indicate defective endochondral ossification. We therefore performed histopathological examination of the distal femur growth plates. As shown in Fig 4, both cases showed a dramatically reduced hypertrophic zone with disorganization of the normal columnar arrangement of chondrocytes. Mutant hypertrophic chondrocytes were also smaller than the corresponding control cells. Case R14-123A had the most severely disrupted morphology, in agreement with the more severe clinical and radiographic phenotype in this case.

Fig 4. Pronounced disorganization of hypertrophic chondrocytes caused by SF3B4 mutations.

Toluidine blue staining of the distal femur growth plate from (A) a control fetus, (B) R14-123A, (C) R08-269A and (D) R08-269B. The hypertrophic zone is marked with double arrows. Images were obtained at 20X magnification. Scale bars are 100 μM.

SF3B4 mutation dysregulates expression of skeletal developmental genes

Cartilage growth plate development is regulated by highly orchestrated cell signaling and transcriptional networks. Profound disorganization of the hypertrophic zone suggested impaired chondrocyte gene expression as a possible result of mutations in SF3B4. We therefore measured growth plate chondrocyte gene expression by RNA-seq using RNA derived from distal femur cartilage from case R08-269A. This analysis identified 2025 differentially expressed transcripts. Among them, 652 transcripts (representing 622 genes) were down-regulated and 1373 transcripts (representing 1215 genes) were up-regulated (S2 Table). Gene ontology (GO) analysis of the down-regulated transcripts primarily revealed altered expression related to skeletal development, transcriptional regulation, chromosome organization and cell cycle control (Fig 5A). Among the down-regulated genes, there were 15 genes, including DLX5 and SOX6, that are known key regulators of skeletal development (Table 2, Fig 5B and 5C). Since SOX9 is is an upstream regulator of SOX6 and plays a pivitol role in chondrocyte differentiation, we examined its expression in the RNA-seq data. As shown in Fig 5D, SOX9 is highly expressed in growth plate chondrocytes and its expression was reduced by 33% in the mutant growth plate. Thus while SOX9 did not meet the screening criteria used to identify differentially expressed genes, its reduced expression was consistent with the secondary reduction of SOX6 transcript levels observed in the RNA-seq data. The SF3B4 transcript level was reduced by 32% in the mutant growth plate (Fig 5E), a result concordant with the quantitative RT-PCR data (Fig 3B).

Fig 5. SF3B4 mutation leads to altered gene expression.

(A) GO analysis of down-regulated genes in growth plate chondrocytes from case R08-269A. The number of genes in each GO term is indicated. (B-E) Expression changes of (B) DLX5, (C) SOX6, (D) SOX9 and (E) SF3B4. The gene expression is represented as FPKM values. (F) Real-time quantitative RT-PCR validation of the RNA-seq data. mRNA expression was normalized to GAPDH. **p<0.01. (G) From top to bottom, enriched DLX5, DLX6, SOX5 and SOX9 binding motifs among the promoter regions of the down-regulated genes. The p values for motif enrichment are shown in parentheses below each motif.

Table 2. Skeletal developmental genes with reduced expression in R08-269A.

To validate the RNA-seq data, we performed quantitative RT-PCR using the same mutant chondrocyte-derived RNA. The data confirmed the observed reduction in DLX5, SOX6, and SOX9 transcript levels (Fig 5F). The expression levels of other U2 snRNP components, SF3B1 and SF3B2, did not show significant differences relative to control chondrocyte RNA. Because it has been shown that DLX6 coordinates with DLX5 in the regulation of craniofacial and limb development, we also examined DLX6 expression using quantitative PCR. While DLX6 had a low expression level in chondrocytes, and therefore did not meet inclusion criteria for determining whether it was differentially expressed in the RNA-seq analysis, by qRT-PCR its expression was significantly decreased in mutant growth plate derived cartilage RNA (Fig 5F).

DLX5/6 proteins and SOX5/6/9 are transcription factors known to regulate chondrocyte gene expression and skeletogenesis [23,24]. SOX5 and SOX6 form dimers and recognize sequences with SOX and SOX-like binding sites [25,26]. We therefore asked whether their targets were enriched among the 652 down-regulated transcripts in SF3B4 mutant growth plate chondrocytes. As shown in Fig 5G, DLX5, DLX6, SOX5 and SOX9 binding motifs were found to be significantly enriched among the promoter regions of the downregulated transcripts (S2 Table), consistent with reduced target gene expression as a regulatory consequence of reduced expression of DLX5/6 and SOX6/9 proteins.

Immunohistochemical staining demonstrated co-localization of expression of SF3B4 and DLX5 in normal human fetal growth plate, with expression in all growth plate chondrocytes and overlapping regions of the periosteum, consistent with their roles in growth plate chondrocyte differentiation and cell signaling (Fig 6). Concordant with their respective functions in splicing and transcription, SF3B4 and DLX5 were specifically localized in chondrocyte nuclei in both wildtype (Fig 6) and mutant growth plates.

Fig 6. SF3B4 and DLX5 are co-expressed in the human growth plate.

Immunohistochemical staining of the distal femur growth plate from a control fetus with (A) anti-SF3B4 and (B) anti-DLX5 antibodies. The hypertrophic zone is marked with double arrows. The periosteum is identified by white arrows. Images were obtained at 20X (SF3B4) and 10X (DLX5) magnification. Scale bars are 100 μM.

Altered RNA splicing in SF3B4 mutant chondrocytes

Because of the role SF3B4 plays in the U2 snRNP complex, the rMATS algorithm was applied to the RNAseq data to determine the effect of reduced SF3B4 on splicing [27]. A total of 1541 significant differential alternative splicing events were identified, which included both exon exclusion (ΔPSI<0) and exon inclusion (ΔPSI>0) scenarios in case R08-269A compared with the controls. These events were divided among five different alternative splicing outcomes. The major effect was exon skipping, with 765 skipped exon (SE) events, including 412 exon exclusions and 353 exon inclusions (Fig 7A and S3 Table). The other four outcomes were 124 mutually exclusive exon (MXE), 134 alternative 5’ splice site (A5SS), 269 alternative 3’ splice site (A3SS) and 249 retained intron (RI) events, with a higher fraction of exon exclusions relative to inclusions (Fig 7A).

Fig 7. SF3B4 mutation leads to altered splicing.

(A) Bar graph representation of altered splicing events in case R08-269A. The number of events in each category is indicated, with exon exclusion to the left (blue bars) and exon inclusion to the right (red bars). (B) GO enrichment analysis of alternative splicing events. The number of genes in each GO term is shown. SE, skipped exon; MXE, mutually exclusive exon; A5SS, alternative 5’ splice site; A3SS, alternative 3’ splice site; RI, retained intron.

RPBJ, HIF1A, SMAD3, and IGF2R are known upstream regulators of SOX9 expression. For all four genes, a minor proportion of their transcripts showed altered splicing, primarily exon skipping or activation of cryptic splice sites (S2 Fig). Among these events, we focused on the abnormal splicing pattern for SMAD3, as its altered splicing was consistent with the observed reduced expression of SOX9. SMAD3 is a component of TGF-β signaling pathway and induces primary chondrogenesis when overexpressed in human mesenchymal stem cells (MSCs). SMAD3 also has been shown to associate with SOX9 on the COL2A1 enhancer to promote SOX9-mediated transcriptional activity, and depletion of SMAD3 in MSCs by siRNA reduces SOX9 expression [28,29]. In case R08-269A, a proportion of SMAD3 transcripts had either inclusion of exon 3 or increased transcription that started from exon 4. Exon 3 encodes a linker region that connects the MH1 and MH2 domains of SMAD3. The SMAD3 splicing variant lacking exon 3 (SMAD3-Δ3) is expressed in multiple human tissues and has positive transcriptional activity [30]. The truncated Smad3 isoform transcribed from an ATG site within exon 4 consists of 7 exons and encodes half of the linker region and the MH2 region. This isoform inhibits activin-induced activation of the FSHβ promoter [31]. Thus together the R08-269A transcripts had reduced expression of the SMAD3-Δ3 transcription activator and increased expression of 5’ truncated transcriptional repressor isoforms, consistent with reduced SMAD3 activity which could lead to reduced expression of SOX9.

Beyond these specific splicing changes, GO analysis of the overall differential alternative splicing events demonstrated enrichment of biological processes relevant to the SF3B4 mutant phenotype, including extracellular matrix organization, skeletal system development, and RNA processing (Fig 7B). These data support a complex effect of altered RNA splicing on downstream gene expression that included signaling molecules, transcription factors and chromatin modifiers that are known to regulate genes essential for skeletal development. Our findings imply that these factors could contribute to the mechanism of disease, but how each molecule individually contributes to this complex phenotype will require development of tissue specific cellular and animal models.


Spliceosomes, large ribonucleoprotein complexes that remove introns from pre-mRNA molecules, are composed of a set of snRNPs, including the U1, U2, U4/U6, and U5 complexes. SF3B4 encodes a core protein in the mammalian SF3B complex, part of the U2-type spliceosome which acts to help tether the U2 snRNP to the branch site [32]. The SF3B4 mutations identified lead to reduced SF3B4 synthesis, altered pre-mRNA splicing and reduced gene expression, ultimately producing the defects in craniofacial and limb development observed in the SF3B4 disorders.

SF3B4 haploinsufficiency and AFD

Haploinsufficiency for SF3B4 is considered to be the major cause of Nager syndrome. In an analysis of 35 independent families with Nager syndrome, Bernier et al. identified 18 cases heterozygous for SF3B4 mutations, including 14 frameshift and two nonsense mutations, indicating that dominant, loss-of-function mutations commonly produce the phenotype [9]. Similarly, in the data presented here, two SF3B4 mutations that were both predicted to result in SF3B4 molecules with altered and extended carboxyl-termini, produced similar but more severe acrofacial dysostosis phenotypes, including one case with the lethal Rodriguez syndrome phenotype. Such mutations are predicted to lead to nonsense-mediated decay of the transcript and in the one case examined the mutant transcript was largely degraded. Whether the small amount of remaining mutant mRNA and the small amount of the abnormal protein (Fig 3D) synthesized by the cells could exert a dominant-negative or gain-of-function effect on the SF3B complex and contribute to the phenotype by altering the splicing function of the complex is unknown. However, it is noteworthy that a case of Nager syndrome with a de novo deletion at chromosome 1q21.2 that covers SF3B4 has been described [33], supporting SF3B4 haploinsufficiency as the primary driver of the craniofacial and limb defects observed in these acrofacial dysostosis phenotypes. The clinical variability in expression across Nager syndrome cases with defects in SF3B4 does suggest that modifiers can influence the phenotype, so it may be that small differences in splicing activity could contribute measureably to phenotypic expression. Interestingly, even the monozygotic twins described here showed some variability in expression, with twin A exhibiting a more severe clinical and radiographic phenotype, suggesting that either epigenetic phenomena or small temporal developmental differences in gene expression can alter the clinical consequences of SF3B4 mutations.

Transcriptional dysregulation by SF3B4 mutation

The RNA-seq data demonstrate that reduced SF3B4 activity can alter gene expression, as in growth plate chondrocytes there were 622 genes that showed reduced expression. Among these are genes known to regulate skeletal system development, consistent with the altered growth plate morphology observed in SF3B4 phenotypes and the ongoing growth deficiency in these disorders. Particularly noteworthy were DLX5 and SOX9, genes with reduced expression and for which mechanistic hypotheses can be advanced to explain some of the skeletal phenotypic features observed in the SF3B4 disorders.

DLX5 and its cis-linked paralogue DLX6 are pivotal regulators of craniofacial and limb development. Dlx5 knockout mice showed craniofacial abnormalities [34] and Dlx5/6−/− mutant embryos exhibited severe limb, craniofacial, and axial skeletal defects [35,36]. Dlx5−/− mice showed a modest defect in chondrocyte hypertrophy in the long bones of the limbs [37], while targeted deletion of both Dlx5 and Dlx6 resulted in more pronounced deficiencies in chondrocyte hypertrophy [36], underscoring their co-regulatory roles in growth plate chondrocyte maturation and endochondral ossification. Reciprocally, forced overexpression of Dlx5 in chondrocytes promoted hypertrophy and induced precocious ossification in the endochondral skeleton [38,39].

In humans, chromosomal rearrangements of the 7q21.3-q22.1 region harboring DLX5, DLX6 and their regulatory elements (including enhancers) have been found in Split-hand/split-foot malformation 1 (SHFM1, OMIM 183600), indicating that structural abnormalities affecting both genes can produce SHFM1 [40,41]. Monoallelic deletion of only the DLX5/6 locus in some cases indicated that DLX5/6 haploinsufficiency can lead to SHFM1 [42]. Point mutations in three SHFM1 families suggest that mutations in DLX5 alone may be sufficient to produce the phenotype [4345]. These data support the idea that the approximately half normal DLX5/6 expression resulting from SF3B4 haploinsufficiency could produce the distal limb abnormalities observed in Nager and Rodriguez syndromes. In addition to the split-hand/split foot phenotype, SHFM1 cases can have craniofacial abnormalities, mesomelic limb malformations, hearing loss, and developmental delay. Since many of these features are shared by Rodriguez/Nager syndrome cases, including cleft palate, micrognathia, and hypoplasia/absence of the radii and fibulae, the reduction of DLX5/6 expression that resulted from reduced SF3B4 expression likely contributes to these aspects of the phenotype as well. Because DLX5/6 transcripts were spliced normally, reduced expression of DLX5/6 due to SF3B4 mutation is likely to be indirect. Multiple mechanisms are known to regulate DLX5/6 expression, including regulation by other transcription factors (e.g. p63, MEF2C) [35,46], by distal regulatory elements (enhancer and noncoding RNA) [4751] and by epigenetic mechanisms [52,53]. SF3B4 mutations may interfere with one or more of these mechanisms and lead to dysregulation of DLX5/6 gene expression.

SOX9 is a transcription factor that regulates skeletal development [5457]. Heterozygosity for mutations in SOX9 produces campomelic dysplasia [54,55], a generally lethal skeletal dysplasia [58]. Most mutations in campomelic dysplasia result in haploinsufficiency for SOX9 and the phenotypic consequences include micrognathia and abnormal ears, as well as distinct skeletal abnormalities. The characteristic skeletal defects include a bell shaped thorax, eleven pairs of ribs, a lateral clavicular hook, hypoplastic scapulae, poor ossification of the pubis, hip dislocations, hypoplastic fibulae, poor ossification of the talus and club feet. The cases with SF3B4 mutations studied here exhibited many of these findings, supporting the inference that the diminished expression of SOX9 transcript due to SF3B4 haploinsufficiency contributes to their skeletal abnormalities. Furthermore, it is known that the skeleton is exquisitively sensitive to SOX9 dosage. Mouse studies show that haploinsuffiency produces a skeletal phenotype similar to campomelic dysplasia in that Sox9+/- mice show hypoplastic scapulae and thin pubic bones [59]. Similar to the consequences of diminished DLX5/6 expression, because SOX9 transcripts appear to be spliced normally, the mechanism for diminished SOX9 transcript may be indirect, but the remarkable phenotypic overlap supports the hypothesis that reduced SOX9 expression has the predictable biological consequences in the SF3B4 disorder phenotypes.

The disrupted hypertrophic zones of the patient growth plates (Fig 4) raise the question of whether downregulation of SOX9 and DLX5 are the cause or consequence of the morphological abnormalities. According to previous studies, Sox9 is expressed in reserve and proliferating chondrocytes but not in the hypertrophic zone [26,60], consistent with an effect on hypertrophic chondrocyte differentiation as a consequence of reduced SOX9. For Dlx5, the gene is expressed throughout the growth plate, including in differentiating proliferative chondrocytes as well as the prehypertrophic and hypertrophic zones [37,39,61]. However, because the hypertrophic zone is much less cellular, loss of hypertrophic chondrocytes could not account for the approximately 50% reduction in DLX5 transcripts. Thus the data again suggest that the morphological alterations are secondary to the reduced expression and not the other way around.

Splicing defects and AFD

The altered splicing and gene expression resulting from SF3B4 mutations echo the spliceosomal defects that have been found to underlie other craniofacial disorders [6]. Haploinsufficiency for EFTUD2, which encodes a GTPase in the U5 snRNP and has a regulatory role in catalytic splicing and post-splicing-complex disassembly, causes mandibulofacial dysostosis of the Guion-Almeida type (OMIM 610536), a disorder that shares many clinical features with Rodriguez/Nager syndromes [7]. EFTUD2 has been shown to interact with SF3B4 by yeast two-hybrid and co-immunoprecipitation studies and it has been suggested that interactions between SF3B and U5 proteins may recruit the tri-snRNP (U4/U6-U5) complex to the spliceosome via the U2 complex [62]. In this study, we identified 1541 alternative splicing events, predominantly exon skipping. As shown here, altered splicing has complex consequences, likely contributing both directly and indirectly to the AFD phenotype, a complexity underscored by alterations in expression of multiple transcription factors known to be essential for normal skeletal development. For the craniofacial dysmorphology in particular, knockdown of Sf3b4 in Xenopus has been shown to result in loss of cranial neural crest cells, demonstrating the importance of normal splicing in maintaining craniofacial skeletal precursors during development [63].

The limb deficiencies and craniofacial dysmophologies found in AFDs with spliceosomal defects indicate that altered splicing/expression of key regulators may lead to developmental abnormalities including early digit patterning and neural crest cell formation and proliferation defects [64], neither of which would be revealed by studying growth plate chondrocytes. For example, p63 is a master trancriptional regulator that controls DLX5/6 expression and skeletogenesis [35,65,66]. p63−/− mice show severely limb and craniofacial defects, and P63 mutations lead to human disorders affecting the facial and limb structures [6569]. Multiple p63 isoforms generated by alternative splicing and promoter usage have been identified, which show distinct roles during endochondral ossification [70]. Therefore, mis-spliced p63 may account for the down-regulation of DLX5/6 in Rodriguez/Nager syndrome cases. However, p63 expression was undetectable in growth plate chondroctyes, suggesting the possibility that earlier developmental events may have led to some of the observed effects on gene expression. Analysis of Sf3b4 deficient animal models will help to identify novel regulators and clarify the role of Sf3b4 in skeletogenesis at early developmental stages.

In addition to the links between splicing and AFD, other mechanisms may also contribute to the phenotype. In this context, SF3B4 has been shown to bind the bone morphogenetic protein (BMP) receptor BMPR-IA and specifically inhibit BMP-mediated osteochondral cell differentiation [71,72]. Thus reduced SF3B4 expression could alter more than one developmental pathway to elicit the observed phenotypes. However, Xenopus Sf3b4 knockdown studies did not confirm a link between SF3B4 expression and BMP signaling alterations [63], indicative of unresolved certainty connecting the SF3B4 disorders and this important skeletal signaling pathway.

In summary, the current study identified heterozygosity for SF3B4 mutations in one case of Rodriguez syndrome and second case with a phenotype intermediate between Rodriguez and Nager syndromes. These data demonstrate that Rodriguez syndrome is a dominant disorder that is allelic with Nager syndrome, and show that the two disorders belong to a spectrum unified by mutations in SF3B4. SF3B4 mutations have also been found in an independent set of Rodriguez syndrome cases (New dominant mutations in SF3B4 encoding an mRNA spliceosomal protein important in embryonic limb patterning underlie Rodriguez acrofacial dysostosis. MD Irving, B Dimitrov, D Chitayat, JI Rodriguez, MW Wessels, MA Simpson. American Society of Human Genetics Meeting, 2014), further supporting this conclusion. Through RNA-seq analysis, mutant growth plate chondrocytes showed altered splicing and reduced expression of transcription factors and additional genes essential for skeletogenesis, suggesting specific regulatory mechanisms that are disrupted in the SF3B4 disorders. Elucidating the direct and indirect effects on the regulatory gene expression pathways affected by SF3B4 mutations is expected to reveal the developmental hierarchy that defines when and how skeletogenesis is altered to produce the SF3B4 phenotypes.

Materials and Methods

Ethics statement

Cases were recruited and informed consent obtained under a UCLA-approved human subjects protocol, through which clinical evaluation and imaging studies, as well as tissue procurement, were carried out.

Cartilage specimen collection and cell culture

Chondrocytes were isolated from distal femur growth plate cartilage from case R08-269A and four independent 14–18 week normal fetal growth plates as described previously [73]. Skin fibroblast cultures were established from explanted skin biopsies from case R14-123A and an unaffected 26-week fetus. Fibroblasts were grown at 37°C in Dulbecco's modified Eagle’s medium plus 10% FBS, penicillin, and streptomycin in 5% CO2.

Genomic DNA isolation and Sanger sequencing

Genomic DNA was isolated from cultured fibroblasts using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s protocol. PCR products were generated with primers flanking each coding exon of SF3B4 (S1 Table) and their sequences determined by bidirectional Sanger sequencing. Electropherograms were analyzed using the CLC Main Workbench (CLC Bio). DNA sequences were compared with the SF3B4 reference genomic sequence (NCBI accession number NG_032777.1).

RNA isolation and quantitative PCR

RNA was isolated from fibroblasts and chondrocytes with TRIZol (Thermo Fisher Scientific) and DNA contamination removed with DNase I (Thermo Fisher Scientific). RNA was reverse transcribed using the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific). Quantitative real-time PCR was performed using SYBR Green Real-Time PCR Master Mix (Thermo Fisher Scientific). Primer sequences for the target genes are listed in the S1 Table. GAPDH was used as a reference gene for normalization. Gene expression was quantified with the ΔΔCT method [74]. Statistical significance was assessed using two-sample Student’s t-test. Sequences of PCR products were determined by Sanger sequence analysis and compared with the NCBI SF3B4 reference sequence (NCBI accession number NM_005850.4).

Western blotting

Cells were lysed in RIPA buffer and proteins separated by electrophoresis on SDS-PAGE gels (Bio-Rad). Proteins were transferred to membranes and probed with anti-SF3B1 (Abcam, ab172634, 1:1000 dilution), anti-SF3B4 N-terminal (Proteintech, 10482-1-AP, 1:1000 dilution), anti-SF3B4 C-terminal (Bethyl Laboratories, A303-950A, 1:1000 dilution) or anti-GAPDH (Cell Signaling Technology, 2118, 1:10000 dilution) antibodies. The ECL kit (Thermo Fisher Scientific) was used to visualize immunoreactive proteins. The level of SF3B4 was quantified with ImageJ software and normalized by comparison with the expression of GAPDH.

Cellular immunofluorescence

Cultured fibroblasts were fixed in 4% PFA, followed by three washes with PBS and one wash with PBST (1% Triton X-100 in PBS). The samples were then blocked in 10% goat serum for 1h and incubated overnight with anti-SF3B4 polyclonal antibody (Proteintech, 10482-1-AP 1:50 dilution). Cell images were captured using confocal fluorescence microscopy (Zeiss).

Cartilage morphology and immunohistochemistry

For Toluidine Blue staining, fetal cartilage samples were fixed in 10% buffered formalin overnight, then washed and transferred to 70% ethanol, dehydrated and embedded without decalcification in methyl methacrylate. The cartilage sections were stained with 0.1% Toluidine Blue. For immunohistochemistry, the paraffin embedded sections were deparaffinized, rehydrated in an ethanol series and permeablilized in 0.5% Triton X-100 before blocking in 10% goat serum and incubating with the primary antibody. The anti-SF3B4 (Proteintech, 10482-1-AP, 1:50 dilution) and anti-DLX5 (Sigma-Aldrich, HPA005670, 1:150 dilution) antibodies were used for staining. The sections were developed with 3,3'-diaminobenzidine (DAB) solution.

RNA-seq and data processing

Total RNA was isolated with TRIZol (Thermo Fisher Scientific) from distal femur growth plate chondrocytes from case R08-269A and four independent 14–18 week fetuses. DNA contamination was removed by DNase I (Thermo Fisher Scientific) digestion at 37°C for 30 minutes. The RNA was further purified with the RNeasy Mini Kit (Qiagen). Total RNA samples with RIN (RNA integrity) numbers ≥ 8 (measured with the Agilent 2100 BioAnalyzer) were used for mRNA library preparation using the TruSeq RNA Preparation Kit (Illumina) according to the manufacturer's instructions. 75bp paired-end reads were generated on the HiSeq 2000 or NextSeq 500 sequencer (Illumina).

RNA-seq reads were mapped to the human genome (hg19) using TopHat (v2.0.9), allowing up to 2-bp mismatches per read [75]. Cufflinks (v2.2.1) was used to calculate RNA-seq based gene expression levels using the FPKM value (fragments per kilobase of exon per million fragments mapped) [76]. Low abundance genes with FPKM values less than 1 were filtered before further analysis. The differentially expressed genes in the case were defined as those genes with more than a 2-fold change in FPKM value compared with the average FPKM value of the normal control samples and more than a 1.5-fold change of FPKM value compared with the maximum or minimum FPKM value of the controls. rMATS (v3.2.1) was used to identify differential alternative splicing events between the case and controls [27]. The change in Percent Spliced In (ΔPSI or Δψ) and false discovery rate (FDR) were used to identify the most significant altered splicing events. The alternative splicing events were filtered using |ΔPSI| > 0.05, FDR < 0.05 and at least 10 reads covering the exon-exon junctions in both case and control samples. Genes with differential expression or alternative splicing were submitted to DAVID for Gene Ontology (GO) analysis [77].

Motif analysis

Enrichment analysis of known transcription factor binding motifs was performed with CentriMo v4.11.1 in the MEME suite [78] using the DNA sequences from gene promoter regions (±1Kb from transcription start sites). Known motifs were obtained from the HOmo sapiens COmprehensive MOdel COllection (HOCOMOCO) v10 [79]. Match score ≥ 5 and E-value ≤ 10 were selected as the report threshold.

Supporting Information

S1 Fig. Prenatal ultrasound images for case R14-123A.

(A,B). Profile showing severe retrognathia and malar hypoplasia. (C) Preaxial polydactyly of the hand (arrow). (D) Low set ears (arrow). (E) Humeral-radial fusion. (F) Bilateral lower extremities showing shortened tibiae and absent fibulae.


S2 Fig. Altered RNA splicing in growth plate chondrocytes.

Sashimi plots of alternatively spliced and flanking exons of (A) SMAD3, (B) IGF2R, (C) RBPJ, and (D) HIF1A. The number of junction reads is indicated within segments. Altered splicing events are indicated by arrows. Exons are numbered and shown at the bottom.


S1 Table. Sequences of primers used in this study.


S2 Table. Gene expression in growth plate chondrocytes and motif analysis.


S3 Table. Alternative splicing events in growth plate chondrocytes from case R08-269A.



We thank the families who participated in the study. We thank the UCLA High-Throughput Sequencing Core in the Broad Stem Cell Research Center and the UCLA Clinical Microarray Core for their assistance with high-throughput sequencing. We thank Tracy Johnson for critically reviewing the manuscript. We are grateful to Melita Irving for sharing data prior to publication.

Author Contributions

  1. Conceptualization: FM JT ID RP DK DHC BL.
  2. Data curation: FM JT ID JM LN DK DHC BL.
  3. Formal analysis: FM ID LN DK DHC BL.
  4. Funding acquisition: RP DHC BL.
  5. Investigation: FM JT ID JM LN DK DHC BL.
  6. Methodology: FM ID JM LN DK DHC BL.
  7. Project administration: DK DHC BL.
  8. Resources: JT DK DHC BL.
  9. Software: BL.
  10. Supervision: RP DK DHC BL.
  11. Validation: FM ID JM LN BL.
  12. Visualization: FM JT ID JM DK DHC BL.
  13. Writing – original draft: FM JT BL.
  14. Writing – review & editing: FM JT ID JM LN RP DK DHC BL.


  1. 1. Wieczorek D (2013) Human facial dysostoses. Clin Genet 83: 499–510. pmid:23565775
  2. 2. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, et al. (2010) Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 42: 30–35. pmid:19915526
  3. 3. Ruiz-Perez VL, Ide SE, Strom TM, Lorenz B, Wilson D, et al. (2000) Mutations in a new gene in Ellis-van Creveld syndrome and Weyers acrodental dysostosis. Nat Genet 24: 283–286. pmid:10700184
  4. 4. Ye X, Song G, Fan M, Shi L, Jabs EW, et al. (2006) A novel heterozygous deletion in the EVC2 gene causes Weyers acrofacial dysostosis. Hum Genet 119: 199–205. pmid:16404586
  5. 5. Weaver KN, Watt KE, Hufnagel RB, Navajas Acedo J, Linscott LL, et al. (2015) Acrofacial Dysostosis, Cincinnati Type, a Mandibulofacial Dysostosis Syndrome with Limb Anomalies, Is Caused by POLR1A Dysfunction. Am J Hum Genet 96: 765–774. pmid:25913037
  6. 6. Lehalle D, Wieczorek D, Zechi-Ceide RM, Passos-Bueno MR, Lyonnet S, et al. (2015) A review of craniofacial disorders caused by spliceosomal defects. Clin Genet 88: 405–415. pmid:25865758
  7. 7. Lines MA, Huang L, Schwartzentruber J, Douglas SL, Lynch DC, et al. (2012) Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly. Am J Hum Genet 90: 369–377. pmid:22305528
  8. 8. Favaro FP, Alvizi L, Zechi-Ceide RM, Bertola D, Felix TM, et al. (2014) A noncoding expansion in EIF4A3 causes Richieri-Costa-Pereira syndrome, a craniofacial disorder associated with limb defects. Am J Hum Genet 94: 120–128. pmid:24360810
  9. 9. Bernier FP, Caluseriu O, Ng S, Schwartzentruber J, Buckingham KJ, et al. (2012) Haploinsufficiency of SF3B4, a component of the pre-mRNA spliceosomal complex, causes Nager syndrome. Am J Hum Genet 90: 925–933. pmid:22541558
  10. 10. Castori M, Bottillo I, D'Angelantonio D, Morlino S, De Bernardo C, et al. (2014) A 22-Week-Old Fetus with Nager Syndrome and Congenital Diaphragmatic Hernia due to a Novel SF3B4 Mutation. Mol Syndromol 5: 241–244. pmid:25337072
  11. 11. Czeschik JC, Voigt C, Alanay Y, Albrecht B, Avci S, et al. (2013) Clinical and mutation data in 12 patients with the clinical diagnosis of Nager syndrome. Hum Genet 132: 885–898. pmid:23568615
  12. 12. Petit F, Escande F, Jourdain AS, Porchet N, Amiel J, et al. (2014) Nager syndrome: confirmation of SF3B4 haploinsufficiency as the major cause. Clin Genet 86: 246–251. pmid:24003905
  13. 13. Dimitrov B, Balikova I, Jekova N, Vakrilova L, Fryns JP, et al. (2005) Acrofacial dysostosis type Rodriguez. Am J Med Genet A 135: 81–85. pmid:15793832
  14. 14. McPherson E, Zaleski C, Ye Z, Lin S (2014) Rodriguez syndrome with SF3B4 mutation: a severe form of Nager syndrome? Am J Med Genet A 164A: 1841–1845. pmid:24715698
  15. 15. Miyawaki M, Higuchi R, Yoshikawa N (2009) Rodriguez lethal acrofacial dysostosis syndrome with pulmonary hypoplasia. Pediatr Int 51: 593–595. pmid:19674374
  16. 16. Petit P, Moerman P, Fryns JP (1992) Acrofacial dysostosis syndrome type Rodriguez: a new lethal MCA syndrome. Am J Med Genet 42: 343–345. pmid:1536176
  17. 17. Rodriguez JI, Palacios J, Urioste M (1990) New acrofacial dysostosis syndrome in 3 sibs. Am J Med Genet 35: 484–489. pmid:2333875
  18. 18. Sermer D, Quercia N, Chong K, Chitayat D (2007) Acrofacial dysostosis syndrome type Rodriguez: prenatal diagnosis and autopsy findings. Am J Med Genet A 143A: 3286–3289. pmid:18000904
  19. 19. Wessels MW, Den Hollander NS, Cohen-Overbeek TE, Lesnik Oberstein MS, Nash RM, et al. (2002) Prenatal diagnosis and confirmation of the acrofacial dysostosis syndrome type Rodriguez. Am J Med Genet 113: 97–100. pmid:12400073
  20. 20. Ansart-Franquet H, Houfflin-Debarge V, Ghoumid J, Pasz N, Devisme L, et al. (2009) Prenatal diagnosis of Nager syndrome in a monochorionic-diamniotic twin pregnancy. Prenat Diagn 29: 187–189. pmid:19180573
  21. 21. Frischmeyer PA, van Hoof A, O'Donnell K, Guerrerio AL, Parker R, et al. (2002) An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 295: 2258–2261. pmid:11910109
  22. 22. Shoemaker CJ, Green R (2012) Translation drives mRNA quality control. Nat Struct Mol Biol 19: 594–601. pmid:22664987
  23. 23. Liu CF, Lefebvre V (2015) The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis. Nucleic Acids Res 43: 8183–8203. pmid:26150426
  24. 24. Zhang H, Hu G, Wang H, Sciavolino P, Iler N, et al. (1997) Heterodimerization of Msx and Dlx homeoproteins results in functional antagonism. Mol Cell Biol 17: 2920–2932. pmid:9111364
  25. 25. Han Y, Lefebvre V (2008) L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage by securing binding of Sox9 to a far-upstream enhancer. Mol Cell Biol 28: 4999–5013. pmid:18559420
  26. 26. Lefebvre V, Li P, de Crombrugghe B (1998) A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J 17: 5718–5733. pmid:9755172
  27. 27. Shen S, Park JW, Lu ZX, Lin L, Henry MD, et al. (2014) rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci U S A 111: E5593–5601. pmid:25480548
  28. 28. Furumatsu T, Ozaki T, Asahara H (2009) Smad3 activates the Sox9-dependent transcription on chromatin. Int J Biochem Cell Biol 41: 1198–1204. pmid:19041414
  29. 29. Furumatsu T, Tsuda M, Taniguchi N, Tajima Y, Asahara H (2005) Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem 280: 8343–8350. pmid:15623506
  30. 30. Kjellman C, Honeth G, Jarnum S, Lindvall M, Darabi A, et al. (2004) Identification and characterization of a human smad3 splicing variant lacking part of the linker region. Gene 327: 141–152. pmid:14980711
  31. 31. Kim SY, Zhu J, Woodruff TK (2011) A truncated, activin-induced Smad3 isoform acts as a transcriptional repressor of FSHbeta expression in mouse pituitary. Mol Cell Endocrinol 342: 64–72. pmid:21664424
  32. 32. Champion-Arnaud P, Reed R (1994) The prespliceosome components SAP 49 and SAP 145 interact in a complex implicated in tethering U2 snRNP to the branch site. Genes Dev 8: 1974–1983. pmid:7958871
  33. 33. Lund IC, Vestergaard EM, Christensen R, Uldbjerg N, Becher N (2016) Prenatal diagnosis of Nager syndrome in a 12-week-old fetus with a whole gene deletion of SF3B4 by chromosomal microarray. Eur J Med Genet 59: 48–51. pmid:26679067
  34. 34. Acampora D, Merlo GR, Paleari L, Zerega B, Postiglione MP, et al. (1999) Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene Dlx5. Development 126: 3795–3809. pmid:10433909
  35. 35. Lo Iacono N, Mantero S, Chiarelli A, Garcia E, Mills AA, et al. (2008) Regulation of Dlx5 and Dlx6 gene expression by p63 is involved in EEC and SHFM congenital limb defects. Development 135: 1377–1388. pmid:18326838
  36. 36. Robledo RF, Rajan L, Li X, Lufkin T (2002) The Dlx5 and Dlx6 homeobox genes are essential for craniofacial, axial, and appendicular skeletal development. Genes Dev 16: 1089–1101. pmid:12000792
  37. 37. Bendall AJ, Hu G, Levi G, Abate-Shen C (2003) Dlx5 regulates chondrocyte differentiation at multiple stages. Int J Dev Biol 47: 335–344. pmid:12895028
  38. 38. Chin HJ, Fisher MC, Li Y, Ferrari D, Wang CK, et al. (2007) Studies on the role of Dlx5 in regulation of chondrocyte differentiation during endochondral ossification in the developing mouse limb. Dev Growth Differ 49: 515–521. pmid:17555518
  39. 39. Zhu H, Bendall AJ (2009) Dlx5 Is a cell autonomous regulator of chondrocyte hypertrophy in mice and functionally substitutes for Dlx6 during endochondral ossification. PLoS One 4: e8097. pmid:19956613
  40. 40. Rasmussen MB, Kreiborg S, Jensen P, Bak M, Mang Y, et al. (2016) Phenotypic subregions within the split-hand/foot malformation 1 locus. Hum Genet 135: 345–357. pmid:26839112
  41. 41. Sowinska-Seidler A, Socha M, Jamsheer A (2014) Split-hand/foot malformation—molecular cause and implications in genetic counseling. J Appl Genet 55: 105–115. pmid:24163146
  42. 42. van Silfhout AT, van den Akker PC, Dijkhuizen T, Verheij JB, Olderode-Berends MJ, et al. (2009) Split hand/foot malformation due to chromosome 7q aberrations(SHFM1): additional support for functional haploinsufficiency as the causative mechanism. Eur J Hum Genet 17: 1432–1438. pmid:19401716
  43. 43. Shamseldin HE, Faden MA, Alashram W, Alkuraya FS (2012) Identification of a novel DLX5 mutation in a family with autosomal recessive split hand and foot malformation. J Med Genet 49: 16–20. pmid:22121204
  44. 44. Wang X, Xin Q, Li L, Li J, Zhang C, et al. (2014) Exome sequencing reveals a heterozygous DLX5 mutation in a Chinese family with autosomal-dominant split-hand/foot malformation. Eur J Hum Genet 22: 1105–1110. pmid:24496061
  45. 45. Sowinska-Seidler A, Badura-Stronka M, Latos-Bielenska A, Stronka M, Jamsheer A (2014) Heterozygous DLX5 nonsense mutation associated with isolated split-hand/foot malformation with reduced penetrance and variable expressivity in two unrelated families. Birth Defects Res A Clin Mol Teratol 100: 764–771. pmid:25196357
  46. 46. Verzi MP, Agarwal P, Brown C, McCulley DJ, Schwarz JJ, et al. (2007) The transcription factor MEF2C is required for craniofacial development. Dev Cell 12: 645–652. pmid:17420000
  47. 47. Birnbaum RY, Everman DB, Murphy KK, Gurrieri F, Schwartz CE, et al. (2012) Functional characterization of tissue-specific enhancers in the DLX5/6 locus. Hum Mol Genet 21: 4930–4938. pmid:22914741
  48. 48. Feng J, Bi C, Clark BS, Mady R, Shah P, et al. (2006) The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes Dev 20: 1470–1484. pmid:16705037
  49. 49. Ghanem N, Jarinova O, Amores A, Long Q, Hatch G, et al. (2003) Regulatory roles of conserved intergenic domains in vertebrate Dlx bigene clusters. Genome Res 13: 533–543. pmid:12670995
  50. 50. Zerucha T, Stuhmer T, Hatch G, Park BK, Long Q, et al. (2000) A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. J Neurosci 20: 709–721. pmid:10632600
  51. 51. Birnbaum RY, Clowney EJ, Agamy O, Kim MJ, Zhao J, et al. (2012) Coding exons function as tissue-specific enhancers of nearby genes. Genome Res 22: 1059–1068. pmid:22442009
  52. 52. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T (2005) Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet 37: 31–40. pmid:15608638
  53. 53. Lilja T, Wallenborg K, Bjorkman K, Albage M, Eriksson M, et al. (2013) Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients. Epigenetics 8: 246–251. pmid:23348913
  54. 54. Wagner T, Wirth J, Meyer J, Zabel B, Held M, et al. (1994) Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell 79: 1111–1120. pmid:8001137
  55. 55. Foster JW, Dominguez-Steglich MA, Guioli S, Kwok C, Weller PA, et al. (1994) Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 372: 525–530. pmid:7990924
  56. 56. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, et al. (1997) SOX9 directly regulates the type-II collagen gene. Nat Genet 16: 174–178. pmid:9171829
  57. 57. Long F, Ornitz DM (2013) Development of the endochondral skeleton. Cold Spring Harb Perspect Biol 5: a008334. pmid:23284041
  58. 58. Maroteaux P, Spranger J, Opitz JM, Kucera J, Lowry RB, et al. (1971) [The campomelic syndrome]. Presse Med 79: 1157–1162. pmid:5555980
  59. 59. Bi W, Huang W, Whitworth DJ, Deng JM, Zhang Z, et al. (2001) Haploinsufficiency of Sox9 results in defective cartilage primordia and premature skeletal mineralization. Proc Natl Acad Sci U S A 98: 6698–6703. pmid:11371614
  60. 60. Kozhemyakina E, Lassar AB, Zelzer E (2015) A pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturation. Development 142: 817–831. pmid:25715393
  61. 61. Ferrari D, Kosher RA (2002) Dlx5 is a positive regulator of chondrocyte differentiation during endochondral ossification. Dev Biol 252: 257–270. pmid:12482714
  62. 62. Hegele A, Kamburov A, Grossmann A, Sourlis C, Wowro S, et al. (2012) Dynamic protein-protein interaction wiring of the human spliceosome. Mol Cell 45: 567–580. pmid:22365833
  63. 63. Devotta A, Juraver-Geslin H, Gonzalez JA, Hong CS, Saint-Jeannet JP (2016) Sf3b4-depleted Xenopus embryos: A model to study the pathogenesis of craniofacial defects in Nager syndrome. Dev Biol.
  64. 64. Dixon J, Jones NC, Sandell LL, Jayasinghe SM, Crane J, et al. (2006) Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities. Proc Natl Acad Sci U S A 103: 13403–13408. pmid:16938878
  65. 65. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714–718. pmid:10227294
  66. 66. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708–713. pmid:10227293
  67. 67. Ianakiev P, Kilpatrick MW, Toudjarska I, Basel D, Beighton P, et al. (2000) Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27. Am J Hum Genet 67: 59–66. pmid:10839977
  68. 68. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, et al. (1999) Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99: 143–153. pmid:10535733
  69. 69. Brunner HG, Hamel BC, Bokhoven Hv H (2002) P63 gene mutations and human developmental syndromes. Am J Med Genet 112: 284–290. pmid:12357472
  70. 70. Lu Y, Abbassi S, Li F, Ding M, Wu G, et al. (2013) Distinct function of P63 isoforms during embryonic skeletal development. Gene 519: 251–259. pmid:23481305
  71. 71. Nishanian TG, Waldman T (2004) Interaction of the BMPR-IA tumor suppressor with a developmentally relevant splicing factor. Biochem Biophys Res Commun 323: 91–97. pmid:15351706
  72. 72. Watanabe H, Shionyu M, Kimura T, Kimata K, Watanabe H (2007) Splicing factor 3b subunit 4 binds BMPR-IA and inhibits osteochondral cell differentiation. J Biol Chem 282: 20728–20738. pmid:17513295
  73. 73. Rock MJ, Holden P, Horton WA, Cohn DH (2010) Cartilage oligomeric matrix protein promotes cell attachment via two independent mechanisms involving CD47 and alphaVbeta3 integrin. Mol Cell Biochem 338: 215–224. pmid:20033473
  74. 74. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408. pmid:11846609
  75. 75. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105–1111. pmid:19289445
  76. 76. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511–515. pmid:20436464
  77. 77. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57. pmid:19131956
  78. 78. Bailey TL, Machanick P (2012) Inferring direct DNA binding from ChIP-seq. Nucleic Acids Res 40: e128. pmid:22610855
  79. 79. Kulakovskiy IV, Vorontsov IE, Yevshin IS, Soboleva AV, Kasianov AS, et al. (2016) HOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models. Nucleic Acids Res 44: D116–125. pmid:26586801